

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.**

( 深圳市海普瑞藥業集團股份有限公司 )

(A listed company on the Shenzhen Stock Exchange, listing code: 002989)

(Stock code: 9989)

**PROFIT WARNING**

This announcement is made by Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the “**Company**”) pursuant to the requirements of Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) for the purpose of providing shareholders of the Company (the “**Shareholders**”) and the public with the financial information of the Company. This announcement is also published in accordance with Rule 13.10B of the Listing Rules as it is also published on the Shenzhen Stock Exchange.

The following is the estimated interim results for the six months ended June 30, 2023 of the Company together with its subsidiaries (the “**Group**”). The financial data contained in this results estimate has not been audited and is, except for non-IFRSs (International Financial Reporting Standards) adjusted net profit attributable to shareholders of the listed company or as otherwise indicated, prepared in accordance with the People’s Republic of China Accounting Standards for Business Enterprises. Detailed financial information of the Group for the six months ended June 30, 2023 (the “**Interim Results**”) will be disclosed in the interim results announcement of the Company for the six months ended June 30, 2023, which is expected to be published on or before August 31, 2023 in accordance with the Listing Rules.

## I. ESTIMATED RESULTS FOR THE PERIOD

1. Period to which the estimated results apply: From January 1, 2023 to June 30, 2023
2. Expected operating results:  Loss  Turnaround  Increase compared with the corresponding period  Decrease compared with the corresponding period

Items	During the Reporting Period	Corresponding Reporting Period
Net profit attributable to shareholders of the listed company	Earnings: RMB98.0 million to RMB127.0 million	Earnings: RMB511.1 million
	Decrease as compared with the corresponding period: 80.83% to 75.15%	
Net profit after non-recurring profit or loss	Earnings: RMB54.0 million to RMB81.0 million	Earnings: RMB504.3 million
	Decrease as compared with the corresponding period: 89.29% to 83.94%	
Basic earnings per share	Earnings: RMB0.0668 per share to RMB0.0866 per share	Earnings: RMB0.3484 per share

## II. COMMUNICATION WITH THE ACCOUNTING FIRM

The relevant data of this results estimate have not been pre-audited by an accounting firm.

### III. REASON FOR CHANGE IN THE RESULTS

During the Reporting period, the heparin industry continued to face the severe challenges of destocking in end markets. The major heparin companies in the world saw a general decrease in their production rates, and the order demand for the active pharmaceutical ingredient (“API”) in heparin declined sharply. In the first half of the year, the export data of China’s heparin API was significantly lower than industry predictions and it is expected that the Company’s API business will be similarly affected. At the same time, due to the destocking, the Company’s finished-dose pharmaceutical business in international non-European and American markets also recorded decreases of varying degrees. On the CDMO business side, the Company saw business income returning to normal. After the order for the key enzymes required for the mRNA COVID-19 vaccine is completed, the new service contracts will require a longer period of time to achieve revenue recognition, putting pressure on the growth of the Company’s CDMO business’ revenue and profit.

During the reporting period, the net loss of HighTide Therapeutics, Inc., an associate of the Company, further increased due to reasons such as changes in the fair value of financial liabilities brought about by the application of listing on the Hong Kong Stock Exchange by HighTide Therapeutics, Inc., and valuation changes. The Company recognized an investment loss of approximately RMB230.0 million according to the accounting treatment for equity method (the same period of last year: RMB55.0 million). As this loss is reflected in the Company’s recurring profit and loss, the net profit during the reporting period has been significantly impacted.

### IV. OTHER RELEVANT INFORMATION

The Company is still in the course of finalizing its consolidated financial results of the Group for the six months ended June 30, 2023. The information contained in this announcement is only based on the preliminary assessment made by the Board of Directors of the Company (the “Board”) by reference to the Group’s unaudited consolidated management accounts and the information currently available to the Board. Such information has neither been confirmed nor audited by the accounting firm of the Company or the audit committee of the Board and may be subject to change. Shareholders and potential investors are advised to refer to the Company’s announcement relating to the interim results of the Group for the six months ended June 30, 2023, which is expected to be published on or before August 31, 2023.

By order of the Board  
HONGKONG PHARMACEUTICAL GROUP, C., LTD.  
L. L.  
Chairman

Shenzhen, the PRC  
July 14, 2023

*As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan, Mr. Shan Yu and Mr. Zhang Ping; and the independent non-executive directors of the Company are Dr. Lu Chuan, Mr. Huang Pang and Mr. Yi Ming.*